Difference between revisions of "Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5 (Q9894)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Volume (P103): 64, #quickstatements; #temporary_batch_1590009084631)
(‎Created claim: title (P93): A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric O...)
 
Property / title
 +
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English)
Property / title: A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English) / rank
 +
Normal rank

Latest revision as of 22:05, 20 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Cooper TM
    0 references
    2017
    0 references
    Pediatr. Blood Cancer
    0 references
    64
    0 references
    A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). (English)
    0 references